$HOWL
Werewolf Therapeutics, Inc. Stock $howl

$howl Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000178553022000031 Filed on August 11, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$4.970M	$4.148M	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$4.439M	$5.233M	$4.421M
YoY Change	10.75%	41.78%	67.78%
% of Gross Profit
Research & Development	$13.07M	$13.89M	$10.95M
YoY Change	33.54%	91.15%	127.22%
% of Gross Profit
Depreciation & Amortization	$404.0K	$185.0K	$98.00K
YoY Change	502.99%	198.39%	151.28%
% of Gross Profit
Operating Expenses	$17.51M	$19.12M	$15.37M
YoY Change	26.92%	74.52%	106.2%
Operating Profit	-$12.54M	-$14.97M	-$15.37M
YoY Change	-9.1%	36.66%	106.2%
Interest Expense	$593.0K	$97.00K	$23.00K
YoY Change	1502.7%	90.2%	-30.3%
% of Operating Profit
Other Income/Expense, Net	$596.0K	$378.0K	$23.00K
YoY Change	1510.81%	980.0%	35.29%
Pretax Income	-$11.94M	-$14.59M	-$15.34M
YoY Change	-13.19%	33.63%	106.36%
Income Tax
% Of Pretax Income
Net Earnings	-$11.94M	-$14.59M	-$15.34M
YoY Change	-13.19%	33.63%	106.36%
Net Earnings / Revenue	-240.3%	-351.83%
Basic Earnings Per Share	-$0.40	-$0.53	-$0.56
Diluted Earnings Per Share	-$0.40	-$0.53	-$0.56
COMMON SHARES
Basic Shares Outstanding	29.53M shares	27.52M shares	27.39M shares
Diluted Shares Outstanding	29.76M shares	27.52M shares	27.39M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$140.5M	$145.7M	$143.7M
YoY Change	-17.59%	-20.48%	69.87%
Cash & Equivalents	$140.5M	$145.7M	$143.7M
Short-Term Investments
Other Short-Term Assets	$6.837M	$6.233M	$1.725M
YoY Change	72.39%	99.39%	555.89%
Inventory
Prepaid Expenses
Receivables
Other Receivables	$4.300M	$2.220M
Total Short-Term Assets	$151.6M	$154.2M	$145.4M
YoY Change	-13.08%	-17.28%	71.37%
LONG-TERM ASSETS
Property, Plant & Equipment	$9.169M	$9.031M	$6.141M
YoY Change	1062.1%	1210.74%	784.87%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$1.853M	$1.855M	$642.0K
YoY Change	52.01%	50.2%	-59.16%
Total Long-Term Assets	$20.84M	$21.16M	$19.20M
YoY Change	424.73%	421.41%	319.93%
TOTAL ASSETS
Total Short-Term Assets	$151.6M	$154.2M	$145.4M
Total Long-Term Assets	$20.84M	$21.16M	$19.20M
Total Assets	$172.4M	$175.3M	$164.6M
YoY Change	-3.34%	-7.92%	84.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.388M	$2.590M	$1.381M
YoY Change	-4.74%	-18.89%	-23.28%
Accrued Expenses	$13.93M	$14.09M	$8.189M
YoY Change	149.98%	307.7%	183.36%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$27.80M	$30.37M	$11.03M
YoY Change	257.56%	312.05%	103.88%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$191.0K	$191.0K	$14.29M
YoY Change
Total Long-Term Liabilities	$191.0K	$191.0K	$14.29M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$27.80M	$30.37M	$11.03M
Total Long-Term Liabilities	$191.0K	$191.0K	$14.29M
Total Liabilities	$41.48M	$45.49M	$25.31M
YoY Change	357.2%	413.29%	256.92%
SHAREHOLDERS EQUITY
Retained Earnings	-$294.8M	-$282.8M	-$268.2M
YoY Change	25.42%	27.82%	74.46%
Common Stock	$3.000K	$2.000K	$2.000K
YoY Change	50.0%	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$130.9M	$129.8M	$139.3M
YoY Change
Total Liabilities & Shareholders Equity	$172.4M	$175.3M	$164.6M
YoY Change	-3.34%	-7.92%	84.08%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$11.94M	-$14.59M	-$15.34M
YoY Change	-13.19%	33.63%	106.36%
Depreciation, Depletion And Amortization	$404.0K	$185.0K	$98.00K
YoY Change	502.99%	198.39%	151.28%
Cash From Operating Activities	-$14.47M	-$303.0K	-$13.95M
YoY Change	16.55%	-97.1%	90.43%
INVESTING ACTIVITIES
Capital Expenditures	-$1.954M	-$1.111M	$28.00K
YoY Change	1815.69%	900.9%	115.38%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$1.954M	-$1.111M	-$28.00K
YoY Change	1815.69%	900.9%	115.38%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	11.08M	3.415M	$159.0K
YoY Change	-4113.04%	-96.9%	-129.55%
NET CHANGE
Cash From Operating Activities	-14.47M	-303.0K	-$13.95M
Cash From Investing Activities	-1.954M	-1.111M	-$28.00K
Cash From Financing Activities	11.08M	3.415M	$159.0K
Net Change In Cash	-5.350M	2.001M	-$13.82M
YoY Change	-58.19%	-97.99%	75.45%
FREE CASH FLOW
Cash From Operating Activities	-$14.47M	-$303.0K	-$13.95M
Capital Expenditures	-$1.954M	-$1.111M	$28.00K
Free Cash Flow	-$12.52M	$808.0K	-$13.98M
YoY Change	1.65%	-107.81%	90.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Central Index Key EntityCentralIndexKey	0001785530
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-40366
	dei	Entity Registrant Name EntityRegistrantName	WEREWOLF THERAPEUTICS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-3523180
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
	dei	Entity Address Address Line1 EntityAddressAddressLine1	200 Talcott Ave
	dei	Entity Address Address Line2 EntityAddressAddressLine2	2nd Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	Watertown
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Ex Transition Period EntityExTransitionPeriod	true
	dei	Entity Shell Company EntityShellCompany	false
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02472
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	952‑05551030 Massachusetts Avenue, Suite 210, Cambridge, Massachusetts 02138(Former name, former address and former fiscal year, if changed since last report)
	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
	dei	Trading Symbol TradingSymbol	HOWL
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	29529425	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145712000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	157531000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	6233000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3537000	usd
CY2022Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	2220000	usd
CY2021Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	154165000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	161068000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9031000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2913000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1208000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	1208000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	9070000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	13412000	usd
CY2022Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1855000	usd
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	649000	usd
CY2022Q2	us-gaap	Assets Assets	175329000	usd
CY2021Q4	us-gaap	Assets Assets	179250000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2590000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2037000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14090000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8765000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1871000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1072000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11817000	usd
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	0	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	30368000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11874000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	13675000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	14589000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1254000	usd
CY2021Q4	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	0	usd
CY2022Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	191000	usd
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	0	usd
CY2022Q2	us-gaap	Liabilities Liabilities	45488000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	26463000	usd
CY2022Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	28456000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	27608000	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	28278000	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	27313000	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	2000	usd
CY2022Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	412671000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	405680000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-282832000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-252895000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	129841000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	152787000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	175329000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	179250000	usd
CY2022Q2	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	4148000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10956000	usd
CY2021Q2	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	4148000	usd
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	0	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13887000	usd
CY2021Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7265000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24832000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12082000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5233000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3691000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9654000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6326000	usd
CY2022Q2	us-gaap	Operating Expenses OperatingExpenses	19120000	usd
CY2021Q2	us-gaap	Operating Expenses OperatingExpenses	10956000	usd
	us-gaap	Operating Expenses OperatingExpenses	34486000	usd
	us-gaap	Operating Expenses OperatingExpenses	18408000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-14972000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30338000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-18408000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	281000	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	265000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-32000	usd
CY2022Q2	us-gaap	Investment Income Net InvestmentIncomeNet	97000	usd
CY2021Q2	us-gaap	Investment Income Net InvestmentIncomeNet	51000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	136000	usd
	us-gaap	Investment Income Net InvestmentIncomeNet	84000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	378000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	35000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	401000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	52000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-14594000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-10921000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-29937000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-18356000	usd
CY2022Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
CY2021Q2	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	56926000	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	0	usd
	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	151942000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14594000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-14594000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-67847000	usd
CY2021Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-67847000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-29937000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-29937000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-170298000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-170298000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.53
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.53
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.82
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.82
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.09
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.09
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-17.86
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-17.86
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27517000	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27517000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	17750000	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	17750000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	27455000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	27455000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9535000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9535000	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	152787000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1745000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	129000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	2379000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	1206000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-15343000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	139318000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	314000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	3339000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1777000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	1000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-14594000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	129841000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-51863000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	-95016000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	539000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	21000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-7435000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	-153754000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Increase In Carrying Amount Of Redeemable Preferred Stock AdjustmentsToAdditionalPaidInCapitalIncreaseInCarryingAmountOfRedeemablePreferredStock	56926000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	293024000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	181556000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-29937000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-18356000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2691000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	2220000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	0	usd
CY2021Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	109221000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	781000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	131000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-10921000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3522000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	1320000	usd
	us-gaap	Depreciation Depreciation	283000	usd
	us-gaap	Depreciation Depreciation	101000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	961000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	336000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	262000	usd
	us-gaap	Increase Decrease In Derivative Liabilities IncreaseDecreaseInDerivativeLiabilities	0	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2726000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	3653000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	0	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	132000	usd
	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	1864000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	3528000	usd
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	13071000	usd
	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	0	usd
	howl	Increase Decrease In Operating Lease Liability And Right Of Use Asset IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset	-115000	usd
	howl	Increase Decrease In Operating Lease Liability And Right Of Use Asset IncreaseDecreaseInOperatingLeaseLiabilityAndRightOfUseAsset	-328000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	191000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-31000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14254000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-17786000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1139000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	124000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1139000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-124000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	109665000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-11819000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	111600000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	239000	usd
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	2087000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	160000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	152000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3574000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	91755000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	158830000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	92777000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	147011000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	184532000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1881000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	15000	usd
	howl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	75000	usd
	howl	Stock Issuance Costs Incurred But Not Yet Paid StockIssuanceCostsIncurredButNotYetPaid	318000	usd
	howl	Stock Option Exercise Receivables In Prepaid Expenses And Other Current Assets StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets	-30000	usd
	howl	Stock Option Exercise Receivables In Prepaid Expenses And Other Current Assets StockOptionExerciseReceivablesInPrepaidExpensesAndOtherCurrentAssets	0	usd
	us-gaap	Accretion Expense AccretionExpense	0	usd
	us-gaap	Accretion Expense AccretionExpense	151942000	usd
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	145700000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. On an ongoing basis, the Company’s management evaluates its estimates which include, but are not limited to, the fair values of common stock and the fair value of the success payment liability. Actual results could differ from those estimates.</span></div>
	us-gaap	Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer	4100000	usd
CY2022Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	11800000	usd
CY2022Q2	us-gaap	Contract With Customer Liability Noncurrent ContractWithCustomerLiabilityNoncurrent	1300000	usd
CY2022Q2	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	674000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	0	usd
	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	15000000	usd
	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1929000	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	13071000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	0	usd
	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	15000000	usd
	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	1929000	usd
CY2022Q2	us-gaap	Deferred Revenue DeferredRevenue	13071000	usd
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	1300000	usd
CY2022Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	100000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9705000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3304000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	391000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	9031000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2913000	usd
	us-gaap	Depreciation Depreciation	300000	usd
	us-gaap	Depreciation Depreciation	100000	usd
CY2022Q2	howl	Accrued Manufacturing Current AccruedManufacturingCurrent	5452000	usd
CY2021Q4	howl	Accrued Manufacturing Current AccruedManufacturingCurrent	3427000	usd
CY2022Q2	howl	Accrued Contract Research Current AccruedContractResearchCurrent	2258000	usd
CY2021Q4	howl	Accrued Contract Research Current AccruedContractResearchCurrent	2542000	usd
CY2022Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	1938000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2200000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1855000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	433000	usd
CY2022Q2	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	1295000	usd
CY2021Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	0	usd
CY2022Q2	howl	Success Payment Liability SuccessPaymentLiability	863000	usd
CY2021Q4	howl	Success Payment Liability SuccessPaymentLiability	0	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	429000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	163000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	14090000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8765000	usd
CY2019Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	9949	sqft
CY2021Q1	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	7500	sqft
CY2021Q2	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	25778	sqft
CY2021Q2	howl	Leasehold Improvements Landlord Allowance LeaseholdImprovementsLandlordAllowance	5700000	usd
CY2021Q2	us-gaap	Security Deposit SecurityDeposit	1000000	usd
CY2022Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	633000	usd
CY2021Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	219000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	1316000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	438000	usd
CY2022Q2	us-gaap	Variable Lease Cost VariableLeaseCost	183000	usd
CY2021Q2	us-gaap	Variable Lease Cost VariableLeaseCost	99000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	281000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	199000	usd
CY2022Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	91000	usd
CY2021Q2	us-gaap	Short Term Lease Cost ShortTermLeaseCost	137000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	228000	usd
	us-gaap	Short Term Lease Cost ShortTermLeaseCost	137000	usd
CY2022Q2	us-gaap	Sublease Income SubleaseIncome	68000	usd
CY2021Q2	us-gaap	Sublease Income SubleaseIncome	0	usd
	us-gaap	Sublease Income SubleaseIncome	68000	usd
	us-gaap	Sublease Income SubleaseIncome	0	usd
CY2022Q2	us-gaap	Lease Cost LeaseCost	839000	usd
CY2021Q2	us-gaap	Lease Cost LeaseCost	455000	usd
	us-gaap	Lease Cost LeaseCost	1757000	usd
	us-gaap	Lease Cost LeaseCost	774000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P7Y7M6D
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.081
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.081
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1453000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	3133000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	2505000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	2337000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2403000	usd
CY2022Q2	howl	Lessee Operating Lease Liability To Be Paid After Year Four LesseeOperatingLeaseLiabilityToBePaidAfterYearFour	8730000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	20561000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5015000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	15546000	usd
CY2022Q2	us-gaap	Debt Instrument Basis Spread On Variable Rate1 DebtInstrumentBasisSpreadOnVariableRate1	0.045
CY2022Q2	howl	Debt Instrument Conditional Fee Liability DebtInstrumentConditionalFeeLiability	900000	usd
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q2	us-gaap	Dividends Payable Current And Noncurrent DividendsPayableCurrentAndNoncurrent	0	usd
CY2022Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2022Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.15
CY2022Q2	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	6597000	shares
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	5264000	shares
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1777000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	781000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3522000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1320000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.48
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	10.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	6.25
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3266000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.24
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y7D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1247000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	9.37
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	47000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	2.81
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	83000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.25
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	4383000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.64
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y9M10D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	1165000	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.40
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y3M14D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	100000	usd
CY2021Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	200000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	usd
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	18800000	usd
CY2022Q2	us-gaap	Sublease Income SubleaseIncome	100000	usd
CY2022Q2	us-gaap	Security Deposit Liability SecurityDepositLiability	200000	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4856000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	3379000	shares

Files In Submission

Name	View Source	Status
0001785530-22-000031-index-headers.html	Edgar Link	pending
0001785530-22-000031-index.html	Edgar Link	pending
0001785530-22-000031.txt	Edgar Link	pending
0001785530-22-000031-xbrl.zip	Edgar Link	pending
a06302022ex311.htm	Edgar Link	pending
a06302022ex312.htm	Edgar Link	pending
a06302022ex321.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
howl-20220630.htm	Edgar Link	pending
howl-20220630.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
howl-20220630_lab.xml	Edgar Link	unprocessable
howl-20220630_cal.xml	Edgar Link	unprocessable
howl-20220630_def.xml	Edgar Link	unprocessable
howl-20220630_pre.xml	Edgar Link	unprocessable
howl-20220630_htm.xml	Edgar Link	completed
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$HOWL
Werewolf Therapeutics, Inc. Stock $howl

2022 Q3 Form 10-Q Financial Statement

#000178553022000031 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOWL Werewolf Therapeutics, Inc. Stock $howl

2022 Q3 Form 10-Q Financial Statement

#000178553022000031 Filed on August 11, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$HOWL
Werewolf Therapeutics, Inc. Stock $howl